Autophagy is an essential component of innate immunity, enabling the detection and elimination of intracellular pathogens. Legionella pneumophila, an intracellular pathogen that can cause a severe pneumonia in humans, is able to modulate autophagy through the action of effector proteins that are translocated into the host cell by the pathogen's Dot/Icm type IV secretion system. Many of these effectors share structural and sequence similarity with eukaryotic proteins. Indeed, phylogenetic analyses have indicated their acquisition by horizontal gene transfer from a eukaryotic host. Here we report that L. pneumophila translocates the effector protein sphingosine-1 phosphate lyase (LpSpl) to target the host sphingosine biosynthesis and to curtail autophagy. Our structural characterization of LpSpl and its comparison with human SPL reveals high structural conservation, thus supporting prior phylogenetic analysis. We show that LpSpl possesses S1P lyase activity that was abrogated by mutation of the catalytic site residues. L. pneumophila triggers the reduction of several sphingolipids critical for macrophage function in an LpSpl-dependent and -independent manner. LpSpl activity alone was sufficient to prevent an increase in sphingosine levels in infected host cells and to inhibit autophagy during macrophage infection. LpSpl was required for efficient infection of A/J mice, highlighting an important virulence role for this effector. Thus, we have uncovered a previously unidentified mechanism used by intracellular pathogens to inhibit autophagy, namely the disruption of host sphingolipid biosynthesis.
(SI Appendix, Fig. S1 ). Structural analysis of SPL from Symbiobacterium thermophilum (StSPL) and Saccharomyces cerevisiae (Dpl1p) identified the residues involved in activity and proposed a mechanism for S1P cleavage (8) . Structural elucidation of human SPL (hSPL) showed that the yeast and the human enzymes adopt largely the same structures (9) .
Recent work suggests a possible link between the role of lipids in the regulation of apoptosis and autophagy (10) . Autophagy is an evolutionary conserved pathway controlling the quality and quantity of eukaryotic organelles and the cytoplasmic biomass. Double-membrane vesicles called "autophagosomes" engulf nonfunctional or damaged cellular components and deliver them to lysosomes, where the content is degraded (11) . Furthermore, it has been shown that autophagy acts as a cell-autonomous defense mechanism against intracellular bacteria, contributing to antibacterial immunity by regulating the inflammatory immune response and routing engulfed intracellular bacteria toward lysosomal degradation (12, 13) . Many pathogens are able to evade autophagy, although the molecular mechanisms at play remain largely uncharacterized (14) (15) (16) (17) (18) (19) (20) . Among these pathogens L. pneumophila is known to escape cellular attack by blocking autophagy defenses (21) . Although it has been reported that L. pneumophila interferes with the autophagy machinery and with host factors that play a role in the cellular defense (22) , only two L. pneumophila proteins that target the autophagy machinery, RavZ and LegA9, have been identified (23, 24) . The bacterial effector RavZ is a cysteine protease that cleaves and causes delipidation of the autophagosome protein LC3, thereby dampening the autophagy process (23, 25) . Interestingly, RavZ is not present in all strains of L. pneumophila, but in all strains tested, L. pneumophila-mediated disruption of autophagosomal maturation delays and/or prevents the Legionella-containing vacuole (LCV) from fusing with lysosomes (26). Thus, L. pneumophila likely also employs other mechanisms to restrain autophagy, and LpSpl, present in all strains sequenced to date, is a good candidate. A first characterization of LpSpl in strain JR32 showed that this protein is secreted by the Dot/Icm type IV secretion system and that it complements the sphingosine-sensitive phenotype of a S. cerevisiae SPL-null mutant, suggesting that it indeed has SPL activity. However, no functional analyses were reported (5) . Thus, we aimed to understand the function of this SPL homolog in L. pneumophila.
Here we report the crystal structure of LpSpl, identify the active site, and show that LpSpl indeed confers S1P lyase activity to L. pneumophila. Its activity during infection leads to the specific reduction of cellular levels of sphingosine, whereas other sphingolipids are down-regulated in a LpSpl-independent manner. Furthermore, we confirm that LpSpl plays a role in delaying the autophagy response of the cell during infection and is important for infection in a pulmonary mouse model of Legionnaires' disease.
Results and Discussion
Crystal Structure of LpSPL Reveals a Dimeric Multidomain Architecture.
hSPL is a single-pass type I integral membrane protein. The region N-terminal to the transmembrane helix is located in the lumen of the endoplasmic reticulum (ER), whereas the C-terminal region faces the cytosol and contains a large enzymatically active domain (27) . We were successful in obtaining well-diffracting crystals of the cytoplasmic fragment of LpSPL spanning residues 56 to the C terminus (LpSpl ). The LpSpl 56-605 structure was solved by single-wavelength anomalous dispersion phasing, using a Se-Metderivatized protein crystal (8) (SI Appendix, Table S2 ). Traceable electron density in the asymmetric unit was observed for two polypeptide chains; however, missing or poor electron density was found in regions throughout each of the chains (Fig. 1A) . The overall structure of the LpSpl protomer could be subdivided into three main regions: an N-terminal region (LpSpl 107/108-57 ), which was missing in our model due to poor electron density; a large cofactor-binding domain (LpSpl ) named the "core" domain, which was largely complete in our structure; and a small C-terminal domain (LpSpl 432-527/529 ). We did not observe electron density for the N-and C-terminal extremities of LpSpl 56-605 , including the above-mentioned residues 56-106 and residues 533-605. The basic architecture of LpSpl was typical of type 1 PLP-dependent enzymes (28), and the presence of an N-terminal region clusters LpSpl with the other characterized SPL enzymes ( Fig. 1 B and C; SI Appendix, S2 A and B). A single chain of LpSpl had a boomerang-like shape, with the N-terminal region and cofactor-binding domains at either end and the C-terminal domain at the apex. The two chains in the asymmetric unit superimposed with an rmsd of 0.5 Å over 328 matching Cα atoms, which excluded the poorly assigned N-terminal domain. LpSpl monomers associated into a homodimer that buried ∼2,500 Å 2 of solvent-inaccessible surface area (Fig. 1B) . The dimer was formed through interactions between the cofactorbinding domains and could be described as a diamond structure with the C-terminal domains at either apex.
As mentioned above, the N-terminal domain in the LpSpl structure was largely disordered except for one helix packed against the solvent-exposed face of the partner chain's cofactorbinding domain away from the active site region (Fig. 1B) . The LpSpl cofactor-binding domain featured a mixed α/β fold (29) and was centered around a seven-stranded β-sheet with two and three helices on either side of the β-sheet. The C-terminal helix of the cofactor-binding domain connected to the C-terminal domain. The C-terminal domain had an α+β structure, composed of a three-stranded β-sheet and three α-helices packed against one face of the β-sheet. Notably, in the human SPL structure, the C-terminal domain featured a two-helix extension connected to the last α-helix of the catalytic domain. This latter element is missing in the crystallized LpSpl fragment due to proteolytic cleavage during crystallization. In accordance with previously characterized SPL structures, the LpSpl structure features a cavity between the N-terminal domain, the cofactor-binding domain, and the C-terminal domain, which corresponded to the PLP-binding active center (Fig. 1B) . However, we did not find any additional density corresponding to a PLP molecule in this region of the LpSpl structure. LpSpl Shows a Conserved Domain Architecture and Active Site Composition Typical for SPL Enzymes. A search for structural homologs using the Dali server confirmed the structures of hSPL (9), yeast Dpl1p, and StSPL (8) as the closest matches for the LpSpl protomer. Each of these structures closely matched the LpSpl structure, with pairwise rmsd values between 2.0 and 2.1 Å over 347-350 matching Cα atoms (e.g., LpSpl 116-529 and hSPL 122-514 ) (SI Appendix, Fig. S2 A and B) . The high level of structural conservation between the structure of LpSpl and eukaryotic SPLs allowed detailed analysis of the LpSpl active center localized at the interface between the two monomers in the dimer (Fig. 2A) . The active center of the LpSpl structure was better resolved for one of the monomers (chain A), whereas several active site residues in the corresponding region in the other monomer (chain B) appear disordered. Of the resolved active site residues, the LpSpl active site was well conserved in amino acid composition and placement compared with the hSPL structure (Fig. 2B) . Specifically, the positions of 11 catalytically important residues were absolutely conserved between the LpSpl and hSPL structures with the 12th residue showing a conservative (Leu to Ile) substitution (Fig. 2B) . The LpSpl K360 residue aligned well with the PLP-conjugating lysine (K353) bound to the PLP molecule in the hSPL structure, suggesting that this LpSpl residue plays a similar functional role. Comparisons of the active site of LpSpl with those from other type 1 PLP-dependent enzymes that showed lower degrees of statistical significance in the Dali search revealed a higher level of sequence and structural divergence. This was seen especially in the sequence and conformation of the loop at the N-terminal end of the cofactor-binding domain (LpSpl 148-164 ).
LpSpl Exhibits Sphingosine-1-Phosphate Lyase Activity During Infection.
The structural analyses ( Fig. 1 B and C; SI Appendix, S2 A and B) and sequence comparison of LpSpl with eukaryotic SPL proteins (SI Appendix, Fig. S2A ) revealed that LpSpl has a conserved active site compared with other SPL enzymes ( Fig. 2 B and C) , strongly suggesting similar enzymatic activity for LpSpl. We therefore analyzed whether LpSpl exhibited S1P lyase activity by using the coumarinic sphinganine 1-phosphate analog, a fluorogenic substrate that is cleaved by SPL in a highly specific manner, producing umbelliferone whose fluorescence was quantified (30). Expression of LpSpl in HEK-293T cells induced significant lyase activity as did mouse SPL (mSPL) used as positive control (Fig. 2C) . We confirmed these results by using a commonly used radiolabeled S1P substrate (SI Appendix, Fig. S2D ). To investigate whether L. pneumophila exhibited lyase activity during infection, we generated an spl mutant strain (Δspl) and infected mouse embryonic fibroblasts lacking the endogenous Sgpl1 gene (MEFspl
−/−
). Whereas cells infected with the Δspl strain did not exhibit lyase activity, the WT bacteria, the complemented strain (Δspl +pKS-LpSpl), as well as the LpSpl-overexpressing strain (WT +pKS-LpSpl) showed lyase activity (Fig. 2D) .
We then undertook mutational analyses of the conserved active site residues to provide evidence into their individual roles in the catalytic activity of LpSpl. We introduced individual alanine substitutions of the active site residues and quantified their in vivo enzymatic activity (SI Appendix, Fig. S2C ). The M228A mutation did not affect SPL activity in agreement with the structure, as this residue is buried against the seven-stranded β-sheet of the cofactor-binding domain and is thus not expected to participate in the enzymatic reaction. In contrast, the mutations C328A and K366A dramatically decreased the enzymatic activity of the enzyme (Fig. 2E) . C328 is solvent-exposed in the active site of LpSpl, and its side chain is closely associated with the side chain of D326 and the backbone oxygen of G220 ( Fig.  2A) . These residues are conserved between LpSpl and hSPL where the corresponding residues in hSPL (G210, C317, and D315) form the PLP-binding pocket (Fig. 2B ). In particular, the side chain of hSPL C317 forms a hydrogen bond with D315, which in turn forms a hydrogen bond with the pyridoxal ring nitrogen and also forms a packing interaction with the pyridoxal ring of PLP. The C328-D326 hydrogen bond is preserved in LpSpl ( Fig. 2A) . Therefore, it is likely that the alanine substitution of LpSpl C328 destabilizes the active site by disrupting PLP binding.
The K366A mutation also drastically decreased the activity of the enzyme (Fig. 2E) . According to the LpSpl structure, this residue is solvent-exposed in the active site and belongs to the same loop (between β6 and β7) as K353, which, through structural comparison with hSPL, forms a Schiff base with PLP ( Fig. 2A) . In the hSPL structure, the equivalent residue (K359) is also solvent-exposed in the active site and is 7 Å from the phosphate group of PLP (Fig. 2B ). Due to its proximity to the PLP and putative substrate-binding region, it is possible that the LpSpl K366A mutation affected interactions with the cofactor and/or substrate. These results confirm that LpSpl is a sphingosine-1-phosphate lyase adopting an active site architecture similar to other characterized sphingosine-1-phosphate lyases. However, LpSPL might have additional activities against other lipid substrates that remain to be discovered.
LpSpl Targets the Sphingolipid Metabolism of the Host Cell. Based on the structural and functional similarity between LpSpl and eukaryotic S1P lyases, we hypothesized that delivery of LpSpl to the host cytoplasm might impact host-cell sphingolipid metabolism. In eukaryotic cells, SPL cleaves S1P to phosphoethanolamine and a fatty aldehyde, which are subsequently reincorporated into glycerolipid metabolic pathways (8) (SI Appendix, Fig. S1 ). To determine whether LpSpl could mimic eukaryotic SPL, we first determined its subcellular localization. Efforts to directly determine the subcellular localization of LpSpl in the host cell were unsuccessful, consistent with previous studies showing that the levels of secretion of Dot/Icm effectors are very low (31-33). However, when transfected with an Xpress-tagged form of LpSpl or a FLAG-tagged form of mSPL, both clearly localized to the ER, as has been reported for hSPL. This finding contrasts with previous reports of the mitochondrial localization of LpSpl (5); nevertheless, coexpression with the ER marker Sec61β and mitotraker staining confirmed localization to the ER (SI Appendix, Fig. S3 ). On the other hand, it has recently been proposed that mammalian SPL might localize to mitochondrial-associated membranes (MAM), specific membrane domains involved in the transfer of de novo-synthesized phospholipids from the ER to the mitochondria (34). Thus, LpSpl may also localize to MAMs. Furthermore, given the important role of the ER in the LCV formation, as well as the role of such membranes in autophagosome formation (35), LpSpl might play a role in driving autophagosome relocation during LCV formation. As the enzymatic activity and the localization determined here suggested that LpSpl acts as eukaryotic SPL, we sought to measure the sphingolipid levels upon infection with L. pneumophila. We hypothesized that the irreversible catalysis of S1P by LpSPL would affect the major sphingolipids to compensate the loss of S1P. THP-1 cells were infected with wild-type L. pneumophila (WT) or the LpSpl mutant strain (Δspl), and the major sphingolipids were quantitatively analyzed by mass spectrometry. After 6 h of infection, several lipid species such as sphingomyelin (SM), ceramide, and glycosphingolipids, were reduced compared with uninfected macrophages. Furthermore, phosphatidylcholine was also reduced, likely due to the choline headgroup exchange compensating for loss of SM (Fig. 3A) . However, the reduced levels of these lipids were not due to LpSpl activity, as macrophages infected with Δspl showed similar levels of lipids as WT-infected cells (Fig. 3A) . It is thus possible that Legionella uses other mechanisms to reduce cellular sphingolipids, which may depend on TLR signaling and/or the presence of additional effectors as at least one gene shows high similarity to mammalian sphingomyelinase (SI Appendix, Fig. S1 ). Although we failed to detect S1P in THP-1 cells (likely due to very low cellular levels), sphingosine levels in macrophages infected with WT and Δspl+pKS-LpSpl were similar to uninfected cells (Fig. 3B) . In contrast, Δspl-infected macrophages showed significantly increased sphingosine levels compared with uninfected or WT-infected macrophages (Fig. 3B) . Thus, we show here, to our knowledge for the first time, that L. pneumophilainfected macrophages show decreased levels of major sphingolipids and that L. pneumophila specifically secretes LpSPL to prevent increased levels of sphingosine.
LpSpl Decreases Starvation-Induced Autophagy. Sphingolipids including ceramide, sphingosine, and S1P have been shown to stimulate macroautophagy (hereafter referred to as "autophagy") (36-38). As autophagy is a cell-autonomous defense mechanism against intracellular bacteria (39) and a relationship between autophagy and sphingosine metabolism is actively discussed in the field (40), we wondered whether LpSpl would modulate autophagy in human cells. Moreover, it has been reported that autophagosomes form at the ER-mitochondria contact sites (35), which is also the localization that we proposed for LpSpl. Furthermore, our data show that infected macrophages show decreased sphingolipid levels, which are impeded by the expression of LpSpl (Fig. 3A) . We thus hypothesized that L. pneumophila employs its LpSpl to dampen autophagy and to promote intracellular survival (21, 41) .
To investigate whether the increased levels of sphingosine in Δspl-infected macrophages resulted in activation of autophagy, we first measured the accumulation of the conjugated form of LC3 (LC3II) in LpSpl-transfected cells (Fig. 3C) . As we have previously demonstrated that S1P contributes to the stimulation of autophagy during starvation (42), we determined the effect of LpSpl expression on starvation-induced autophagy by quantifying the LC3II/actin ratio in starved cells (EBSS) supplemented or not with Bafilomycin-A1 (BafA1). BafA1 prevents maturation of autophagic vacuoles by inhibiting lysosome-autophagosome fusion and blocking LC3II degradation (43). Indeed, we detected a lower amount of LC3II in cells expressing LpSpl or mSPL, compared with cells transfected with the empty vector, suggesting that LpSpl impairs the formation of autophagosomes ( (Fig. 3D ). In accordance with these results, the degradation of long-lived proteins in starved cells, which largely depends on autophagy (44), was severely impaired in cells expressing LpSpl (SI Appendix, Fig.  S4B ). The inhibitory effect of LpSpl on LC3-II accumulation is in agreement with the function of mSPL, as its ectopic expression also resulted in a decreased starvation-induced autophagy as detected both by counting LC3-positive cells and by LC3II accumulation ( Fig. 3D ; SI Appendix, S4B). Taken together, our data show that LpSpl activity inhibits autophagosome formation and not autophagosome maturation, as RavZ does (25) . To further analyze this finding, we studied autophagosome maturation in transfected cells by using an RFP-GFP-LC3 tandem system (SI Appendix, Fig. S5 A and B), which allows us to follow autophagosometo-autolysosome conversion under starvation conditions (SI Appendix, Fig. S5C ). Ectopic expression of either LpSpl or mSPL in the absence of BafA1 did not impact the ratio between autophagosomes and autolysosomes, confirming that SPL acts at the stage of autophagosome biogenesis (SI Appendix, Fig. S5D ). This result is in line with a recent report that suggests that S1P is an initiator of autophagosome formation and SPL an inhibitor of autophagy in primary cells (45). Thus, ectopic expression of LpSpl can prevent autophagosome formation under nutrient limiting conditions. To understand at which stage LpSPL affects the autophagy pathway, we analyzed the activation of the kinase TOR (mTOR in mammals), which forms a large complex called mTORC1 that assembles under the tight control of cellular nutrient availability and negatively controls autophagy (46). Phosphorylation of 4EBP1 and S6, direct effectors of the mTORC1 complex, was unaffected upon transfection of eukaryotic cells with either LpSPL or mSPL, suggesting that SPL activity impacts the autophagy pathway downstream from the mTOR pathway (SI Appendix, Fig. S6A ). To confirm that the action of LpSpl required its enzymatic activity, we ectopically expressed mutant forms of LpSpl (K366A, C328A, and M228A; Fig. 2E ) in cells and measured both LC3 II accumulation (SI Appendix, Fig. S6B ) and degradation of the autophagy cargo p62/SQSTM1. Autophagic clearance of protein aggregates requires ubiquitin-binding proteins such as p62/SQSTM1, which are selectively incorporated into autophagosomes through direct binding to LC3 (47, 48). Thus, the total cellular expression levels of p62 inversely correlate with autophagy activity. As shown in Fig.  3E , LpSpl and mSPL expression indeed induced an accumulation of p62 compared with starved control cells, and its accumulation was clearly dependent on LpSpl activity. The catalytically inactive mutants K366A and C328A did not induce an accumulation of p62 levels, whereas in cells transfected with the M228A mutant LpSpl, which does not affect the enzyme activity (Fig. 2E) , an accumulation of p62 comparable to the WT protein was detected (Fig. 3E) . These results are in agreement with the LpSpl active site architecture observed in the crystal structure and with the in vivo SPL activity assays.
LpSpl Restrains the Host Autophagy Response During L. pneumophila Infection. To determine the impact of LpSpl activity during infection, we quantified the inhibition of autophagy in infected human macrophages. We performed high-content image-based assays to automatically quantify the number of cells with LC3 puncta in a high number of cells (SI Appendix, Fig. S7 ). THP-1 cells were infected with either WT or the Δspl mutant strain at different time points, and the accumulation of LC3 puncta was quantified as a function of time (Fig. 4A) . We observed a reduction of LC3 accumulation in WT-infected cells from 8 to 20 h of infection (Fig. 4A) . In contrast, at 20 h postinfection, single-cell analysis of cells infected with the Δspl strain showed, despite a large variance and a wide distribution in the data, a significant increase of cells with LC3 puncta compared with WT-infected cells (Fig. 4 B and C), pointing to a role of LpSpl in restraining autophagy during infection of human macrophages. These results are in agreement with previous observations that L. pneumophila tends to limit the autophagy response of the host cell during intracellular replication (21, 49) and identified a L. pneumophila effector implicated in modulating autophagy. To understand the interplay of the different effectors that manipulate autophagy, we analyzed also the L. pneumophila strain Philadelphia that encodes RavZ and LpSpl. We constructed a ΔravZ, Δspl, and a Δspl/ravZ double mutant in the strain Philadelphia and analyzed the accumulation of LC3 puncta for these strains. As expected the contribution of RavZ to inhibiting the autophagy machinery is much stronger than that of LpSpl probably because RavZ is directly targeting LC3 (Fig. 4D) . However, ravZ is present neither in the L. pneumophila strain Paris nor in about 40% of the L. pneumophila strains sequenced to date, revealing that L. pneumophila has evolved several effectors, including LpSpl, that inhibit the autophagy machinery at different stages.
To investigate whether LpSpl played a role in the virulence of L. pneumophila, we analyzed the intracellular replication of the WT or the Δspl strain in amoeba (Acanthamoeba castellanii) (SI Appendix, Fig. S8A ). We observed a slightly impaired infection capacity but similar replication of the Δspl as also reported previously (5) . This result is comparable to that observed for RavZ, as its deletion had no measurable impact on intracellular replication (23) . Interestingly, intracellular replication assays in human-derived macrophages (THP-1) suggested that the Δspl strain replicates slightly better than the WT strain (SI Appendix, Fig. S8B) , similarly to what was observed for a deletion mutant of LegA9, which also plays a role in the autophagy response (24) . Thus, L. pneumophila has evolved several strategies to restrain autophagy. However, the important role of autophagy in controlling L. pneumophila infection is evident when comparing the growth rate of L. pneumophila in WT and Atg9 −/− Dictyostelium discoideum. L. pneumophila replicated better when the autophagy machinery was impaired by disrupting ATG9 in D. discoideum (SI Appendix, Fig. S9A ) (24, 50) . Similarly, mSPL also contributes to restriction of L. pneumophila growth, as deletion of the gene encoding mSPL enhances intracellular replication of L. pneumophila (SI Appendix, Fig. S9B ). Thus, L. pneumophila possesses different effectors modulating the autophagic machinery, each having a distinct role in modulating the fine balance of autophagy. Furthermore, each one of these effectors alone does not show a strong replication phenotype when deleted, further suggesting that interference with the autophagy response is particularly fine-tuned and that our infection assays are too crude to accurately measure these small differences or that these differences can be observed only in in vivo infection models. This hypothesis is supported by the fact that LpSpl is required for optimal replication of L. pneumophila in a pulmonary mouse model of infection (Fig. 4E) . Intratracheal colonization of A/J mice revealed that Δspl bacteria were outcompeted by WT L. pneumophila 72 h after infection with a competitive index < 0.5 (mean 0.26 ± 0.35, P < 0.0001, one sample t test with theoretical mean of 1.00). Thus, L. pneumophila lacking LpSpl was not able to establish an efficient infection in competition with WT L. pneumophila.
In conclusion, we report here the structure and function of, to our knowledge, the first translocated bacterial effector that directly targets the host-cell sphingolipid metabolism to change the fine balance of the different signaling molecules. The crystal structure of LpSpl identified the active site, and its comparison with hSPL together with the characterization of its enzymatic activity revealed that L. pneumophila uses molecular mimicry of eukaryotic SPLs to alter sphingolipid levels of the infected host cell through its S1P lyase activity. LpSpl likely depletes S1P and reduces autophagy in the host cell, contributing to counteracting the antibacterial response of the host cell.
Materials and Methods
The materials and methods are described at length in SI Appendix. They include protein purification and crystallography, lipidomics, SPL activity assays, cloning, bacterial strain and mutant constructions, cell culture and infection assays, pulmonary infection of A/J mice (all animals were handled in strict accordance with good animal practice as defined by the Melbourne University Animal Ethics Committee, approval number 1112061.6), Western blotting, immunofluorescence microscopy, and statistical analyses. Throughout the article for significance we used *P < 0.05, **P < 0.01, and ***P < 0.001. Table S2 : X-ray diffraction data collection and structure refinement statistics 15 16 Figure S1: Schematic overview of the sphingolipid pathway. terminal MBP-TVMV-His 6 tag followed by a TEV protease recognition and cleavage site.
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MBP-His 6 -tagged LpSpl proteins were expressed and purified as previously described (1). were also analyzed by electrospray ionisation-mass spectrometry (ESI-MS) using an Agilent respectively. In all cases, the collision gas was nitrogen at SPL activity assays. SPL activity was measured as previously described (9) . Briefly, 48h were BamHI-digested and ligated with kan R cassette. ravZ was inactivated by introducing a 149 apramycin resistance cassette. The mutant allele was constructed using a 3-steps PCR. and mouse embryonic fibroblasts (MEFs) wt and knockout for the spl gene (MEFs-spl -/-) (13).
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Cells was maintained in 5% CO2 at 37°C in supplemented 10% fetal bovine serum A. castellanii and of 10 for THP-1; mean ± SD; n=3). 
